Immunotherapy for Non-small Cell Lung Cancer

Guest Editors:

Prof. Dr. Ramon Andrade De Mello
1. Precision Oncology & Health Economics Group, Post-graduation program in medicine, Faculty of Medicine, Nine of July University, São Paulo, Brazil
2. Division of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil
3. Algarve Biomedical Center, University of Algarve, Faro, Portugal
ramello@ualg.pt

Prof. Nam P. Nguyen
Department of Radiation Oncology, Howard University College of Medicine, Washington, DC, USA
nam.nguyen@howard.edu

Deadline for manuscript submissions: closed (12 November 2021)

Message from the Guest Editors

Dear Colleagues,

Non-small cell lung cancer (NSCLC) is a disease with high mortality world-wide. However, treatment approaches have been improving in the last few decades. Several immune checkpoints inhibitors acquired an important role in the clinical practice either in the adjuvant or in metastatic setting. Thus, this Special Issue will focus in the basic, translational, and clinical research in the field of immunotherapy in order to understand the future trends in this field.

Prof. Dr. Ramon Andrade De Mello
Prof. Nam P. Nguyen
Guest Editors

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of this format.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Alaska Anchorage, Anchorage, AK, USA

Special Issue
Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Certainly, there is a need to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPplus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q2 (Oncology)

Contact Us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
www.mdpi.com
mdpi.com/journal/cancers
cancers@mdpi.com
@Cancers_MDPI